East China Pharmaceuticals: Application for market authorization of Regorafenib Injection accepted

East China Pharmaceuticals announced that on May 29, 2025, its wholly-owned subsidiary Hangzhou Zhong Mei Huadong Pharmaceutical Co., Ltd. received a "Notice of Acceptance" issued by the National Medical Products Administration for the market approval application of Lenzilumab Injection. The drug is used for the treatment of various retinal diseases in adults and premature infants, with a total research and development investment of approximately 220 million yuan. The acceptance of the market approval application for Lenzilumab Injection is another important milestone in the drug's development process, and it will not have a significant impact on the company's current performance. However, it will help enhance the company's core competitiveness in the field of this treatment in the long run.